CLBT: Federal AI And Cloud Adoption Will Support Premium P/E Potential

Analysts have nudged the fair value estimate for Cellebrite DI slightly lower from $21.67 to $21.00, tying this adjustment to modestly revised assumptions for revenue growth, profit margins, and future P/E multiples, following recent research that highlights both multiple compression and a large, growing addressable market.

Analyst Commentary

Recent research highlights a mix of optimism and caution on Cellebrite DI, with views anchored in the size of the opportunity, the pace of recurring revenue growth, and the impact of multiple compression on valuation.

Bullish Takeaways

Bullish analysts point to a large and growing total addressable market, which they see as potentially understated. This supports the case for long-term revenue expansion if the company executes on product adoption and customer penetration.
There is an emphasis on multiple drivers of wallet share gains with existing customers. If realized, these could support higher recurring revenue and provide more visibility into future cash flows.
Guided organic annualized recurring revenue growth acceleration is cited as a key execution milestone. Bullish analysts see progress toward this goal as supportive of current fair value assumptions.
Some research sets price targets around US$20, which is close to the updated fair value estimate. This suggests analysts see room for the stock to align more closely with their assessed intrinsic value if the company meets its growth and margin objectives.

Bearish Takeaways

Bearish analysts focus on multiple compression, which has led to lower price targets. This reflects concern that valuation may be sensitive to shifts in market sentiment or sector-wide P/E resets even when fundamentals are stable.
One firm reduced its target from US$18 to US$15 despite Q1 results that outperformed consensus estimates. This signals that solid quarterly execution alone may not fully offset valuation headwinds.
The gap between different analyst price targets indicates uncertainty around how quickly wallet share gains and recurring revenue acceleration can translate into sustained earnings and cash flow growth.
Some caution that expectations for the addressable market and recurring revenue may already be embedded in current models. This may limit upside if the company delivers only in line with existing guidance rather than exceeding it.

What's in the News

Cellebrite DI reports a rebound in its U.S. federal business, with management pointing to stronger demand in this segment and projecting faster federal growth in 2026, supported by AI-enabled solutions such as the new Genesis agentic AI platform. Source: Recent news summary
The company reports a 21% year over year change in first quarter annual recurring revenue and a 35% change in the U.S. federal sales pipeline, reflecting higher subscription exposure and a growing pipeline of federal opportunities. Source: Recent news summary
Cellebrite Government Cloud receives FedRAMP High Authorization, which is the highest security level in the FedRAMP framework for sensitive unclassified federal data, with the U.S. Department of Justice acting as the sponsoring agency and enabling broader use across federal departments. Source: Key Developments
Cellebrite introduces new AI driven products, including early access to the Genesis agentic AI investigation platform and general availability of Guardian Investigate, an AI powered investigative management solution aimed at speeding up complex digital investigations and case collaboration. Source: Key Developments
The company issues second quarter 2026 guidance, expecting revenue in a range of US$130 million to US$133 million, with annual growth in a range of 15% to 17%. Source: Key Developments

Valuation Changes

Fair Value: Updated to $21.00 from $21.67, a small reduction that reflects modest tweaks to the underlying assumptions.
Discount Rate: Kept effectively unchanged at 10.57%, indicating no material shift in the required return used in the valuation model.
Revenue Growth: Trimmed slightly to 17.40% from 17.51%, suggesting a marginally more conservative view on future dollar revenue expansion.
Net Profit Margin: Adjusted modestly lower to 16.97% from 17.19%, pointing to a slightly more cautious stance on future profitability.
Future P/E: Reduced to 52.48x from 63.81x, a meaningful step down that accounts for lower assumed valuation multiples in the forecast period.

9 views

Key Takeaways

Accelerating digital crime and security demands are boosting adoption of Cellebrite's forensic SaaS platforms, driving strong subscription growth and deeper customer relationships.
Emphasis on privacy compliance, AI innovation, and recurring revenue is expanding market opportunities, supporting premium pricing, and improving margins and valuation prospects.
Heavy reliance on US federal contracts, regulatory headwinds, and competition-driven R&D needs threaten Cellebrite's growth, margins, and diversification, increasing risks of revenue volatility and market erosion.

Catalysts

About Cellebrite DI

Develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific.What are the underlying business or industry changes driving this perspective?

The accelerating shift by law enforcement and intelligence agencies toward more advanced digital investigation platforms, driven by surging digitalization, larger data volumes, and increasing crime sophistication, is fueling rapid adoption of Cellebrite's cloud/SaaS solutions and digital forensics platforms (Inseyets, Guardian, Pathfinder), which is set to drive continued double-digit subscription revenue and ARR growth over the coming years.
Heightened global security focus, including rising budgets for defense and intelligence (especially in Europe amid geopolitical tension and in the US as new federal allocations are released), is expected to result in a sharp resurgence of demand and larger contract values in 2026, supporting a return to higher top-line growth and increased customer stickiness.
Strengthening privacy and data protection regulations are paradoxically expanding the need for Cellebrite's forensically-sound, compliant data access and investigation tools, reinforcing the company's competitive positioning, supporting premium pricing, and helping sustain high gross margins.
Ongoing innovation in AI-powered analytics and automation, as well as the integration of strategic acquisitions like Corellium (expanding access to ARM device forensics and new private sector verticals), is set to increase Cellebrite's total addressable market (TAM), improve product differentiation, and support both revenue and margin expansion over the long term.
The continued transition to a recurring, subscription-based revenue model-with over 90% of revenues now from subscriptions and growing SaaS/cloud penetration-improves revenue visibility, predictability, and operating leverage, which is already translating into higher EBITDA and free cash flow margins and is likely underappreciated in current valuations.

Cellebrite DI Earnings and Revenue Growth

Cellebrite DI Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Cellebrite DI's revenue will grow by 17.4% annually over the next 3 years.
Analysts assume that profit margins will increase from 14.4% today to 17.0% in 3 years time.
Analysts expect earnings to reach $136.3 million (and earnings per share of $0.45) by about June 2029, up from $71.4 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $122.4 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 52.6x on those 2029 earnings, up from 49.6x today. This future PE is greater than the current PE for the US Software industry at 30.0x.
Analysts expect the number of shares outstanding to grow by 0.82% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 10.57%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Cellebrite's over-reliance on U.S. federal government contracts introduces significant revenue instability; ongoing delays and constrained visibility into federal spending cycles, combined with procurement and budget bottlenecks, led management to lower guidance and signal that near-term ARR growth is materially impacted-with the company explicitly noting that the federal segment's slow recovery subtracts approximately 4 percentage points from total ARR growth for 2025, directly limiting revenue and earnings growth.
Heightened competition and rapid advances in mobile OS security (notably Apple and Google anti-forensics measures) continue to necessitate escalating R&D investment to sustain Cellebrite's lawful access capabilities; if device manufacturers and privacy advocates successfully harden devices or limit data accessibility faster than Cellebrite can innovate, the long-term relevance and pricing power of Cellebrite's solutions may erode, compressing margins and jeopardizing market share.
Increasing global privacy regulations and tightening data protection laws (such as GDPR, CCPA, and new standards emerging in Europe and other regions) could place greater restrictions on digital evidence extraction, potentially shrinking Cellebrite's addressable market, adding compliance costs, and placing downward pressure on future revenue growth-especially as public and political resistance to digital surveillance grows.
Although international and private sector expansion are highlighted as growth drivers (with recent momentum in EMEA, Latin America, and early Corellium sales), the company's commentary indicates these segments remain a small portion of overall revenue-leaving Cellebrite exposed to geographic and customer concentration risk that could limit earnings diversification and increase volatility during sector-specific demand shocks.
Ambitious investments in AI-driven innovation and acquisitions (such as Corellium) carry execution and integration risks; failure to deliver anticipated operational efficiencies, premium product capabilities, or market expansion could result in elevated costs without corresponding revenue or gross margin improvement, constraining net income and potentially disappointing investors counting on high-margin, innovation-led growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $21.0 for Cellebrite DI based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $28.0, and the most bearish reporting a price target of just $15.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $803.2 million, earnings will come to $136.3 million, and it would be trading on a PE ratio of 52.6x, assuming you use a discount rate of 10.6%.
Given the current share price of $14.18, the analyst price target of $21.0 is 32.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Cellebrite DI?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Cloud SaaS Solutions Will Drive Digital Forensics Adoption